Research from our lab and others showed that the mechanistic/mammalian target of rapamycin (mTOR) drives several different aspects of cerebrovascular dysfunction in models of AD [3] and vascular cognitive impairment and dementia (VCID) [4], including blood-brain barrier (BBB) breakdown, cerebral hypoperfusion, reduced cerebrovascular reactivity, and impaired neurovascular coupling (please see [5] for a review of these mechanisms). This evidence concerns the gene MTOR and Alzheimer disease.